Pfizer

Events

Partner Content

Adaptive Designs in Clinical Trials 2019

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019.

News

Merck and Pfizer chalk up another fail for Bavencio

Merck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in ovarian cancer, denting their hopes of building momentum for the product.

News

Pfizer to hike prices of 41 drugs despite Trump criticism

Pfizer plans to raise the prices of 41 prescription drugs in January, despite falling foul of President Trump, who criticised the company’s stance on costs earlier this summer.

Digital

The future of pharma in a digital world

How is digital health impacting pharma? An exclusive live broadcast from Frontiers Health 2018 addressed this subject on 15 November.

News

Pfizer hit by UK Supreme Court ruling on Lyrica patent

Pfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to claims for hundreds of millions of pounds from the NHS.

News

FDA green lights Pfizer's Lorbrena for aggressive lung cance...

Pfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer.

Adaptive Designs in Clinical Trials 2019

Merck and Pfizer chalk up another fail for Bavencio

Pfizer to hike prices of 41 drugs despite Trump criticism

The future of pharma in a digital world

Pfizer hit by UK Supreme Court ruling on Lyrica patent

FDA green lights Pfizer's Lorbrena for aggressive lung cance...

Gilead strikes again, penning $5bn deal to buy Tubulis

Using AI-driven synthetic personas to take your insights fur...

Pfizer

Editor's Picks